Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Nepuvibart (ZRC3308-B10), an IgG1 type anti-SARS-CoV-2 monoclonal antibody, exhibits strong binding affinity to a distinct non-competing epitope on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. When combined in a 1:1 ratio with ZRC3308-A7, Nepuvibart is effective in preventing COVID-19 and in treating the early stages of the disease before it progresses to severe illness [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Nepuvibart (ZRC3308-B10), an IgG1 type anti-SARS-CoV-2 monoclonal antibody, exhibits strong binding affinity to a distinct non-competing epitope on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. When combined in a 1:1 ratio with ZRC3308-A7, Nepuvibart is effective in preventing COVID-19 and in treating the early stages of the disease before it progresses to severe illness [1]. |
Molecular Weight | N/A |
CAS No. | 2640224-48-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Nepuvibart 2640224-48-0 inhibitor inhibit